89424-17-9

Usage

Uses

Used in Pharmaceutical Industry:
3-OXO-3-(2-TRIFLUOROMETHYLPHENYL)PROPIONIC ACID ETHYL ESTER is used as an intermediate in the synthesis of various drugs for its potential analgesic and anti-inflammatory properties. Its unique structure, including the trifluoromethyl group, makes it a valuable precursor for the development of new medications with improved therapeutic effects.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3-OXO-3-(2-TRIFLUOROMETHYLPHENYL)PROPIONIC ACID ETHYL ESTER serves as a key building block for the synthesis of biologically active compounds. Its unique properties and structural features make it an attractive candidate for the design and development of novel pharmaceutical agents with enhanced efficacy and selectivity.
Used in Drug Discovery and Development:
3-OXO-3-(2-TRIFLUOROMETHYLPHENYL)PROPIONIC ACID ETHYL ESTER is utilized in drug discovery and development processes to explore its potential as a lead compound for the treatment of various diseases and conditions. Its unique chemical properties and structural features make it a promising candidate for further optimization and modification to improve its pharmacological profile and therapeutic potential.

Upstream product

• 433-97-6 2-trifluoromethylbenzoic acid 
• 6148-64-7 ethyl potassium malonate 

Downstream Products

• 76345-08-9 3-dimethylamino-2-(2-trifluoromethyl-benzoyl)-acrylic acid ethyl ester 
• 76344-91-7 5-[2-(trifluoromethyl)phenyl]isoxazole-4-carboxylic acid ethyl ester 
• 1003561-80-5 5-[2-(trifluoromethyl)phenyl]isoxazole-4-carboxylic acid 
• 1224944-83-5 [5-(2-trifluoromethyl-phenyl)-isoxazol-4-yl]-carbamic acid tert-butyl ester 
• 1224944-84-6 5-chloro-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [5-(2-trifluoromethyl-phenyl)-isoxazol-4-yl]-amide 
• 1224942-10-2 5-amino-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [5-(2-trifluoromethyl-phenyl)-isoxazol-4-yl]-amide 
• 929602-16-4 4-phenyl-2-(3-(trifluoromethyl)phenyl)quinoline 

Relevant academic research and scientific papers

Synthesis of Dithiolethiones and Identification of Potential Neuroprotective Agents via Activation of Nrf2-Driven Antioxidant Enzymes

Oxidative stress is implicated in the pathogenesis of a wide variety of neurodegenerative disorders, and accordingly, dietary supplement of exogenous antioxidants or/and upregulation of the endogenous antioxidant defense system are promising for therapeutic intervention or chemoprevention of neurodegenerative diseases. Nrf2, a master regulator of the cellular antioxidant machinery, cardinally participates in the transcription of cytoprotective genes against oxidative/electrophilic stresses. Herein, we report the synthesis of 59 structurally diverse dithiolethiones and evaluation of their neuroprotection against 6-hydroxydopamine-or H2O2-induced oxidative damages in PC12 cells, a neuron-like rat pheochromocytoma cell line. Initial screening identified compounds 10 and 11 having low cytotoxicity but conferring remarkable protection on PC12 cells from oxidative-mediated damages. Further studies demonstrated that both compounds upregulated a battery of antioxidant genes as well as corresponding genes' products. Significantly, silence of Nrf2 expression abolishes cytoprotection of 10 and 11, indicating targeting Nrf2 activation is pivotal for their cellular functions. Taken together, the two lead compounds discovered here with potent neuroprotective functions against oxidative stress via Nrf2 activation merit further development as therapeutic or chemopreventive candidates for neurodegenerative disorders.

PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS

The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.